Among the 11,385 participants in the analysis sample for AST, ALT, and DRR, 2643 (23.2%) were sonographically diagnosed with moderate to severe hepatic steatosis, while in the analysis sample for GGT, 2075 (23.4%) of the 8879 participants were sonographically diagnosed with moderate to severe hepatic steatosis. This evidence concerns the gene GPT and fatty liver disease.